Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Noteable

T.ONC

RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

August 22, 2024 - China approves KRAS G12C inhibitor developed by Chinese...

August 22, 2024

T.ONC

RE:Antibody-Drug Conjugate (ADC) developments

August 22, 2024 - Health Canada has granted approval of KEYTRUDA® ...

August 22, 2024

T.ONC

Antibody-Drug Conjugate (ADC) developments

https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=35525030

August 22, 2024

T.ONC

RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

https://www.biospace.com/business/wuxi-biologics-takes-net-profit-hit-despite...

August 22, 2024

T.ONC

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

ONCY's acquisition value is worth multiples of its aggregated R&D...

August 21, 2024

T.ONC

RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

ONCY has approximately $500 million in R&D expenses that can be...

August 21, 2024

T.ONC

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

Why the United States Can’t Afford to Lose Its Biopharma Industry The...

August 21, 2024

T.ONC

RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

August 21, 2024 - In a letter to FDA Commissioner Robert Califf, a House...

August 21, 2024

T.ONC

RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Don't worry about Matt .... he's entirely pre-occupied in the...

August 20, 2024

T.ONC

RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

ONCY will have 13 years of FDA marketing exclusivity from the date of FDA...

August 20, 2024

T.ONC

RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

According to an October 2023 paper in the Oncologist regarding the '...

August 20, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Should read : " ....  and in a basic way explain how ONCY'...

August 20, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

As part of the pro-inflammatory activity, certain signals, referred to...

August 20, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Berry et.al. (2020) "  ...data demonstrate that crosslinking...

August 20, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Daichii Sanyo's Enhertu consists of a HER2 monoclonal antibody...

August 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

  All FDA Approved ADC Therapies  ...

August 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

In a key mechanism of ADCs, once the antibody part of the drug binds to the...

August 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

" Merck’s sac-TMT is an antibody-drug conjugate (ADC) targeting...

August 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Additionally Stewart et.al. (2019) found that "topoisomerase inhibitors...

August 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Should read : ONCY's pelareorep, which enhances topoisomerase I...

August 18, 2024

Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next

Featured Company

GameSquare Holdings Inc.

GameSquare Holdings Inc. GAME

GameSquare Holdings, Inc. is a vertically integrated, digital media, entertainment and technology company. It connects global ... view more »